Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres-Reference-Cited by-同舟云学术

Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres

Published:2020-04-24 Issue:3 Volume:26 Page:487-493
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Soucie John Michael¹²^ORCID,Miller Connie H.¹²,Dupervil Brandi¹,Le Binh¹,Buckner Tyler W.³

Affiliation:

1. Division of Blood Disorders Centers for Disease Control and Prevention Atlanta GA USA

2. Synergy America, Inc. Duluth GA USA

3. Division of Hematology University of Colorado School of Medicine Aurora CO USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13998

Reference20 articles.

1. Occurrence of hemophilia in the United States

2. Population‐based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources

3. Community counts: Evolution of a national surveillance system for bleeding disorders

4. Definitions in hemophilia: communication from the SSC of the ISTH

5. United States Department of Health and Human Services (U.S. DHHS) Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS) Bridged‐Race Population Estimates United States July 1st resident population by state county age sex bridged‐race and Hispanic origin. Compiled from 1990–1999 bridged‐race intercensal population estimates (released by NCHS on 7/26/2004); revised bridged‐race 2000–2009 intercensal population estimates (released by NCHS on 10/26/2012); and bridged‐race Vintage 2017 (2010–2017) postcensal population estimates (released by NCHS on 6/27/2018). Available on CDC WONDER Online Database. Accessed athttp://wonder.cdc.gov/bridged‐race‐v2017.html on Mar 11 2019.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions;Pediatric Drugs;2024-08-05

2. The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B;Journal of Managed Care & Specialty Pharmacy;2024-08

3. Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States;Journal of Managed Care & Specialty Pharmacy;2024-08

4. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States;Journal of Medical Economics;2024-06-06

5. Race and ethnicity reporting and representation in hemophilia clinical trials;Blood Advances;2024-05-17